Regulus Therapeutics (RGLS) Reports In-Line Q3 EPS

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.50), in-line with the analyst estimate of ($0.50).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Robinhood prices $2B convertible notes offering due 2029
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs